| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541035 | SAPTALIS PHARMS | Oral formulations of metronidazole and methods of treating an infection using same |
Oct, 2039
(15 years from now) | |
Likmez is owned by Saptalis Pharms.
Likmez contains Metronidazole.
Likmez has a total of 1 drug patent out of which 0 drug patents have expired.
Likmez was authorised for market use on 22 September, 2023.
Likmez is available in suspension;oral dosage forms.
The generics of Likmez are possible to be released after 04 October, 2039.
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 22 September, 2023
Treatment: NA
Dosage: SUSPENSION;ORAL
More Information on Dosage
LIKMEZ family patents
